Emergent BioSolutions | EBS - Trade Creditors


Emergent BioSolutions reported $112.2M in Trade Creditors for its fiscal quarter ending in December of 2023.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
Akebia Therapeutics USD 8.39M 12.8M Mar/2026
ALKERMES USD 102.36M 5.59M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Amarin USD 48.15M 2.8M Mar/2026
ANI Pharmaceuticals USD 69.69M 7.11M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Coherus Biosciences USD 9.91M 14.98M Dec/2025
Emergent BioSolutions USD 112.2M 500K Dec/2023
Exelixis USD 24.15M 5.47M Mar/2026
Glaxosmithkline GBP 20.72B 346.14M Dec/2025
Heron Therapeutics USD 8.97M 24K Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
Ironwood Pharmaceuticals USD 3.24M 339K Mar/2026
Lexicon Pharmaceuticals USD 3M 87K Mar/2026
Lonza CHF 471M 3M Dec/2024
Merck USD 3.86B 541M Mar/2026
Moderna USD 161M 156M Mar/2026
Myriad Genetics USD 32.6M 2.6M Mar/2026
Nektar Therapeutics USD 10.77M 4.79M Dec/2025
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Pacira USD 14.01M 1.14M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
PTC Therapeutics USD 25.48M 20M Mar/2026
Sanofi EUR 22.71B 219M Mar/2026
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
United Therapeutics USD 498.3M 491.2M Mar/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024
Xoma USD 2.65M 1.52M Sep/2025